Biological warfare

Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens

Retrieved on: 
Wednesday, October 25, 2023
CRADA, Ageing, Cooperative research and development agreement, Therapy, Maxwell, United States Army Medical Research and Development Command, Biological warfare, U.S. Army Public Health Center, United States Army Medical Research Institute of Infectious Diseases, Development, USAMRIID, McClure, Infection, Peptide, Vaccine

USAMRIID to study antiviral activity of Claromer technology against national priority biodefense threats

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • "As a military veteran, I'm proud to lead a team that tirelessly seeks to fill critical unmet needs for more effective therapeutics against the worst global pathogens."
  • "Our Claromer technology has the potential to replace almost all antibiotics, antifungals and antivirals - and it may help with healthy aging as well," continued McClure.
  • "Signing this CRADA with USAMRIID, the world's preeminent biodefense research organization, is another validation of Maxwell's Claromer technology's potential as an important, disruptive platform technology."

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Retrieved on: 
Tuesday, September 19, 2023
Ochsner Medical Center, ASPR, Burkholderia pseudomallei, Plague, Emergency, Biomedical Advanced Research and Development Authority, CBRN, Office of Inspector General, U.S. Department of Health and Human Services, HHS, Administration for Strategic Preparedness and Response, Public, Infection, Tularemia, Public Health Service Act, Unitary state, Typhus, Biosafety, Glanders, Yersinia pestis, Government, Melioidosis, Bacillus anthracis, Burkholderia mallei, Development, Administration, Disaster, MRIGlobal, Francisella tularensis, Biological warfare, Public health, Patient, Rickettsia prowazekii, Bacillus, Mortality, FDA, Anthrax, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, Food, Pharmaceutical industry, Vaccine, Medical device

LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel.
  • The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.
  • The U.S. clinical evaluation to support the FDA 510(k) submission included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in biothreat pathogens, and Ochsner Medical Center.
  • The T2Biothreat Panel is able to detect the six aforementioned biothreat pathogens within four hours providing clinicians with the needed information to appropriately treat infected patients.

Global Biodefence Market Report 2023: Increasing List of Bio-threat Agents Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 13, 2023
Pharmaceutical, Health, Defense, Other Defense, Vaccine, Travel, Internet, Anxiety, Infection, Bioterrorism, Biological warfare, Clinical epidemiology, Government, Market, Death, Botulism, Investment, Developed country, Economic development, R, Anthrax, News, Social media, Clothing, Video game, Fine chemical, Renewable energy, Beauty salon, Sales, Biodefense

The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing awareness regarding bioterrorism attacks in developed as well as underdeveloped economies will significantly fuel the biodefence market growth over the forecast period.
  • Minimal government intervention and low R&D funding in underdeveloped regions will impede the biodefence market growth over the forecast period.
  • Where is the Biodefence Market heading and how can you ensure you are at the forefront of the market?

T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel

Retrieved on: 
Tuesday, May 23, 2023
Burkholderia pseudomallei, Plague, Biomedical Advanced Research and Development Authority, U.S. Department of Defense Strategy for Operating in Cyberspace, Public, Infection, Office of Inspector General, U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Tularemia, Typhus, Glanders, Yersinia pestis, Melioidosis, Bacillus anthracis, Burkholderia mallei, Administration, Development, Francisella tularensis, Biological warfare, Public health, Patient, Rickettsia prowazekii, Bacillus, Mortality, Health, FDA, Anthrax, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, Food, Vaccine, Pharmaceutical industry

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the Company’s T2Biothreat™ Panel.
  • The FDA submission follows the recently completed U.S. clinical evaluation that demonstrated very high sensitivity and specificity, and included 350 contrived positive samples and over 470 negative blood samples from both healthy and febrile subjects.
  • "This FDA submission marks an important milestone in our commitment to protect Americans from the threat of deliberate or naturally occurring outbreaks of biothreat pathogens,” stated John Sperzel, Chairman and CEO of T2 Biosystems.
  • The T2Biothreat Panel is able to detect the aforementioned biothreat pathogens within 4 hours and provide clinicians with the needed information to appropriately treat infected patients.

T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

Retrieved on: 
Monday, February 13, 2023
Administration, Francisella tularensis, Anthrax, Office of Inspector General, U.S. Department of Health and Human Services, Tularemia, Burkholderia mallei, Food and Drug Administration, Development, Plague, Patient, Biosafety, BARDA, Clinical trial, Yersinia pestis, Glanders, Food, Health, Melioidosis, Bacillus anthracis, Burkholderia pseudomallei, Mortality, U.S. Department of Defense Strategy for Operating in Cyberspace, MRIGlobal, Typhus, Biological warfare, Biomedical Advanced Research and Development Authority, FDA, Public health, Bacillus, Public, Infection, Administration for Strategic Preparedness and Response, Vaccine, Pharmaceutical industry, Rickettsia

LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.

Key Points: 
  • LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel.
  • “We are extremely pleased with the results of the clinical evaluation.
  • Rapid detection of these pathogens is essential to getting infected patients on the appropriate antimicrobial therapy and improving clinical outcomes.
  • The results of the clinical trial demonstrated very high sensitivity and specificity across all six targets.

Global CBRN (Chemical, Biological, Radiological and Nuclear) Defense Market Report 2022-2026: Military Spending in the Wake of the Russia Ukraine War, CBRN Defense Solutions are Poised to Benefit - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Other Defense, Defense, Radiation, Global, Laboratory, Infection, Plague, Engineering, COVID-19, Smallpox, Risk, Fever Dream, Virus, Role, Good Times, Nature, Chemical substance, Gene, Chemical warfare, Acquisition, Growth, Weapon, Biological warfare, Anthrax, Typhus, CBRN defense, Threat, Program, CBRN, Defense, Technology, Inhalation, Public health, Bacteria, Solution, Human back, Death, Research, DNA, Physics, Biology, Immune system, Genetic code, Chemistry, Spore, CAGR, Pet, Vaccine, Pharmaceutical industry, EU

Biological warfare holds serious concerns as the technology linked with production of these weapons is comparatively affordable and is easy to access.

Key Points: 
  • Biological warfare holds serious concerns as the technology linked with production of these weapons is comparatively affordable and is easy to access.
  • The acquisition along with dissemination of some of the restricted organisms such as Variola major is possible.
  • Russia has alleged that Ukraine and the US are working with pathogens known to cause serious infections in various laboratories.
  • Pandemic Fails to Deter Global Military Spending, Which Spirals to All Time High in 2021, a Sign of Good Times to Prevail for CBRN Defense

Global Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Market 2022-2026: Development of Polymer Nanofibers and New Variants of CBRN Protective Devices Through Technological Advances - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Other Defense, Defense, Lists of weapons, CBRN, Hearing protection device, Biological warfare, Medical imaging

The "Global Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • Also, development of polymer nanofibers and new variants of CBRN protective devices through technological advancements will lead to sizable demand in the market.
  • The chemical, biological, radiological, and nuclear defense (CBRND) market analysis includes the product segment and geographic landscape.
  • Also, the chemical, biological, radiological, and nuclear defense (CBRND) market analysis report includes information on upcoming trends and challenges that will influence market growth.

‘Superantigen’ Identified in COVID Spike Protein May Cause Heart Damage, according to the Journal of American Physicians and Surgeons

Retrieved on: 
Monday, June 6, 2022
Vaccination, Degenerative disease, SEB, National, Journal, Syndrome, Biological warfare, National academy, AAPS, Muscle tissue, Physician, Association of American Physicians and Surgeons, GLOBE, Blunt cardiac injury, Patient, RNA transfection, Technology, COVID-19, Severe acute respiratory syndrome coronavirus 2, Association, Attention, Pharmaceutical industry, Vaccine, Surgeon

A detailed look at the spike protein of the SARS-CoV-2 virus and the protein coded for by the mRNA vaccine reveals the presence of a superantigen motif.

Key Points: 
  • A detailed look at the spike protein of the SARS-CoV-2 virus and the protein coded for by the mRNA vaccine reveals the presence of a superantigen motif.
  • But it is similar both in function and three-dimensional structure to staphylococcal enterotoxin B. SEB is a potent toxin produced by Staphylococcus aureus bacteria.
  • Since there is no apparent natural evolutionary lineage for the superantigen sequence, a laboratory origin must be considered, he states.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Ameresco Awarded 6-MW Battery Energy Storage System (BESS) at U.S. Army’s Fort Detrick Base

Retrieved on: 
Wednesday, May 4, 2022
White House, Federal Government, Other Energy, Utilities, Homeland Security, Other Defense, Defense, Alternative Energy, Contracts, Public Policy, Government, Environment, Energy, Zero, Farnan, Renewable energy, Soldier, Army of the United States, Engineer, Defense, OEI, World War II, U.S. Army Corps of Engineers, Europe District, NYSE, Engineering, Federal, Government, Bulgarian–American Joint Military Facilities, Carbon, Army, Fort Detrick, Natural gas, Partnership, Biological warfare, Coal, BESS, Kilowatt-hour, Fortification, Garrison, Corps, Electricity, AMRC, Quality of life, Defense Logistics Agency, RESA, Assistant, Technology, Environment, Research, Assistant Secretary of the Army for Installations, Energy and Environment, Work, Acquisition, WWII

In partnership with DLA Energy, Ameresco will deploy a 6 MW / 6 MWh BESS on the 67-acre facility.

Key Points: 
  • In partnership with DLA Energy, Ameresco will deploy a 6 MW / 6 MWh BESS on the 67-acre facility.
  • We commend the Army for taking yet another step to improve their energy infrastructure through battery energy storage technologies at Fort Detrick, said Nicole Bulgarino, Executive Vice President, Ameresco.
  • To learn more about the renewable energy, resiliency, and energy efficiency solutions offered by Ameresco, visit www.ameresco.com/renewable-energy/ .
  • DLA Energy Installation Energy Division provides acquisition support for facility energy commodities and services including coal, natural gas, electricity, renewable energy, energy savings performance contracts and long-term renewable energy project development.

TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures

Retrieved on: 
Thursday, March 17, 2022
Department, Research, Technology, Development, Absorption, School of Advanced Warfighting, United States Army Medical Research Institute of Infectious Diseases, Skin, Risk, Biosafety level, United States Army Medical Research and Development Command, Defense, Temperature, RVSV-ZEBOV vaccine, Inhalation, Veteran, Solubility, COVID-19, Government, Infection, Pandemic, Freezing, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Biosafety, Program, Health, Therapy, Nose, NASDAQ, Severe acute respiratory syndrome coronavirus 2, TFF, Biological warfare, GLOBE, Annual report, Military, Vaccine, FDA, Institute, Safety, CRADA, Company, Military medicine, Pharmaceutical industry, Virology

Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.

Key Points: 
  • Army Medical Researchand Development Command and theU.S Army'spremier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.
  • Current medical countermeasures have become less effective in recent months as new COVID-19 variants have emerged, saidGlenn Mattes, President & Chief Executive Officer ofTFF Pharmaceuticals.
  • TFF Pharmaceuticals continues to engage with various government and defense contracting agencies to utilize its Thin Film Freezing technology platform to formulate dry powder vaccines and therapeutics for mucosal delivery.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability.